Related Experiment Video
Updated: Dec 20, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Psoriasis, biologic therapy, and the pandemic of the 21st century
Miguel Nogueira1, Ron Vender2, Tiago Torres1,3
1Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal.
Abstract:
The pandemic known as coronavirus disease-19 (COVID-19) has quickly spread worldwide, with a significant impact on lives all over the world. The complexity related to the new coronavirus and the clinical syndrome it causes is not yet fully understood. The impact of COVID-19 on patients with psoriasis under biologic agents is continuously being observed in this rapidly changing pandemic. A case-by-case evaluation must be made by dermatologists, and the final decision should be discussed and decided by both the patient and the specialist. Observations reveal that immunosuppressive therapy may have a role in the treatment of this virus, placing emphasis on the scenario of safety through maintenance of therapy with biologic agents, especially when there are no signs or symptoms related to the infection or contact with an infected patient.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
Drug Products: Biologics, Biosimilars and Interchangeables
EPS and iPS Cells in Disease Research
